USS Investment Management Ltd Has $5.11 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

USS Investment Management Ltd boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 19.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,444 shares of the medical equipment provider’s stock after acquiring an additional 9,228 shares during the quarter. USS Investment Management Ltd’s holdings in Zimmer Biomet were worth $5,105,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Inceptionr LLC bought a new position in Zimmer Biomet during the 3rd quarter worth $1,217,000. PNC Financial Services Group Inc. grew its position in shares of Zimmer Biomet by 9.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after buying an additional 13,883 shares during the last quarter. Wilsey Asset Management Inc. acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $32,439,000. Dimensional Fund Advisors LP raised its position in shares of Zimmer Biomet by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,269,122 shares of the medical equipment provider’s stock worth $223,503,000 after acquiring an additional 39,146 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Zimmer Biomet by 257.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after acquiring an additional 24,748 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ZBH shares. Citigroup lowered their price target on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a report on Thursday, May 28th. Truist Financial reissued a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Leerink Partners initiated coverage on Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price target for the company. Finally, Citizens Jmp lowered their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $102.70.

Insiders Place Their Bets

In related news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Trading Up 4.0%

NYSE:ZBH opened at $87.50 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $16.93 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 2.48 and a beta of 0.46. The firm has a fifty day simple moving average of $86.20 and a two-hundred day simple moving average of $89.83. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s payout ratio is presently 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.